

# MDA HEALTH PLAN BOARD MEETING PENDING REFERRALS

STATUS	REFERRAL
Ongoing	<b>Meeting as of February 4, 2022</b> Review of plan investment portfolio manager every five years beginning in 2024. (Start/Winn)
<input type="checkbox"/> NA	<b>Meeting as of June 17, 2022</b> Revisit proposal to offer incentives to members with complex medical needs to complete a consult with a pharmacist regarding specialty drugs
<input type="checkbox"/> NA	Provide further information on the Medication Therapy Management program
<input checked="" type="checkbox"/> X	Premium rebalancing strategy to be proposed
<input checked="" type="checkbox"/> X	Respond to the DOL NQTL audit by 7/3/2022
<input checked="" type="checkbox"/> X	Initiate four plan changes for 2023 a. Shut down Plans 7 & 9 b. Add allergy testing and weight loss drug benefit to all plans c. Add \$0 deductible plan d. Add fertility benefit up to a maximum lifetime benefit of \$30,000 to all plans
<input checked="" type="checkbox"/> X	<b>Meeting as of November 4, 2022</b> None
<input checked="" type="checkbox"/> X	<b>Meeting as of February 3, 2023</b> Check to see which weight loss drugs plan members are using Revisit re-balancing strategy in June Re-visit plans in one year to see if significant savings are available with telehealth Bid COBRA vendor out
<input checked="" type="checkbox"/> X	<b>Meeting as of May 5, 2023</b> None